The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.